MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Adds background in paragraphs 6-10, Zenas BioPharma debut in paragraph 11
Sept 13 (Reuters) -Shares of MBX Biosciences MBX.O, which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, jumped nearly 44% in their Nasdaq debut on Friday.
The upbeat debut underscores investors' growing focus on weight-loss drugs after proving to be an effective obesity treatment and showing potential to reduce stroke or heart attack risks.
The stock opened at $23 apiece, valuing the biotech firm at about $694 million.
MBX said on Thursday it had raised $163.2 million by selling 10.2 million shares at $16 apiece — the high-end of its targeted range of $14 to $16 each — in its initial public offering.
The U.S. IPO market is on a route to recovery, albeit uneven, after a two-year dry spell, on hopes of a possible rate cut by the Federal Reserve and lower market volatility.
MBX's success fares well for the IPO market that went into a traditional summer lull following the debut of cold storage real estate investment trust Lineage LINE.O in July, the biggest this year.
MBX's lead experimental candidate, MBX 2109, is being developed to treat chronic hypoparathyroidism — a condition in which the body produces insufficient levels of parathyroid hormone that disrupts calcium levels in the blood and bones.
The company is also developing MBX 4291, an experimental therapy for the treatment of obesity. The therapy mimics the effect of two gut hormones, GLP-1 and GIP.
Eli Lilly's LLY.N tirzepatide, sold as Zepbound for weight loss and Mounjaro for diabetes in the United States, also mimics the function of these two gut hormones.
Wall Street estimates annual global sales of $150 billion for weight-loss drugs by the early 2030s.
Separately, Bristol-Myers Squibb-backed Zenas BioPharma also debuted on the Nasdaq, with its shares rising nearly 8%.
Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Shilpi Majumdar
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
